SplitMay 13, 2026, 10:02 PM
Propanc Biopharma Announces 1-for-25 Reverse Stock Split
AI Summary
Propanc Biopharma's Board of Directors approved a 1-for-25 reverse stock split, effective May 18, 2026. This action will reduce the outstanding common shares from approximately 56.96 million to 2.28 million on a pro forma basis. The company is implementing the split to regain compliance with Nasdaq's $1.00 minimum bid price requirement and support its growth plans, including advancing its lead asset PRP to a Phase 1b clinical study.
Key Highlights
- Board approved a 1-for-25 reverse stock split on March 16, 2026.
- Split is anticipated to be effective before market open on May 18, 2026.
- Outstanding shares will reduce from ~56.96M to ~2.28M pro forma.
- Fractional shares will be rounded up to the nearest whole share.
- Split aims to restore Nasdaq $1.00 minimum bid price compliance.
- Common stock will trade under existing symbol "PPCB" with new CUSIP.